Prestige Consumer Healthcare (NYSE:PBH) Downgraded to Strong Sell Rating by Zacks Research

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings lowered shares of Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Jefferies Financial Group decreased their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Canaccord Genuity Group decreased their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Finally, Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $70.75.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $46.49 on Monday. Prestige Consumer Healthcare has a 52 week low of $42.62 and a 52 week high of $89.24. The stock has a market cap of $2.20 billion, a P/E ratio of 11.89, a P/E/G ratio of 1.50 and a beta of 0.40. The business’s 50 day moving average price is $57.03 and its 200-day moving average price is $61.17. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The firm had revenue of $281.62 million during the quarter, compared to analysts’ expectations of $293.64 million. During the same quarter in the previous year, the firm earned $1.32 earnings per share. Prestige Consumer Healthcare’s revenue was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Equities research analysts anticipate that Prestige Consumer Healthcare will post 4.43 earnings per share for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the transaction, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of PBH. UMB Bank n.a. boosted its holdings in shares of Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock valued at $26,000 after purchasing an additional 219 shares during the last quarter. Bayforest Capital Ltd bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at about $29,000. Barrow Hanley Mewhinney & Strauss LLC boosted its holdings in shares of Prestige Consumer Healthcare by 106.8% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after purchasing an additional 283 shares during the last quarter. Geneos Wealth Management Inc. boosted its holdings in shares of Prestige Consumer Healthcare by 92.8% during the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after purchasing an additional 269 shares during the last quarter. Finally, Torren Management LLC bought a new position in shares of Prestige Consumer Healthcare during the 4th quarter valued at about $35,000. Institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).